B. Riley Research Analysts Lift Earnings Estimates for DNLI

Key Points

• B. Riley Research has raised its Q3 2025 EPS estimate for Denali Therapeutics from ($0.86) to ($0.79), expecting a total FY2025 earnings of ($3.08) EPS.
• Denali Therapeutics reported a Q2 loss of ($0.72) EPS, slightly beating analysts' expectations of ($0.74).
• Current coverage shows a majority of analysts giving Denali Therapeutics a "Buy" rating, with a consensus price target of $33.85.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at B. Riley upped their Q3 2025 EPS estimates for Denali Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.79) per share for the quarter, up from their previous forecast of ($0.86). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics' Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.08) EPS, FY2026 earnings at ($2.68) EPS, FY2027 earnings at ($1.66) EPS and FY2028 earnings at ($2.47) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the previous year, the firm earned ($0.59) earnings per share.

DNLI has been the subject of a number of other reports. William Blair raised shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Wedbush dropped their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Bank of America dropped their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Robert W. Baird lowered their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $33.85.

Denali Therapeutics Trading Up 1.7%

Shares of Denali Therapeutics stock opened at $14.70 on Monday. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. The stock has a market cap of $2.15 billion, a PE ratio of -5.25 and a beta of 1.36. The company has a 50-day moving average of $14.30 and a two-hundred day moving average of $15.25.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth about $55,224,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Denali Therapeutics by 88.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company's stock valued at $91,996,000 after buying an additional 3,184,042 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Denali Therapeutics by 15.9% in the 1st quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company's stock valued at $155,113,000 after buying an additional 1,561,647 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Denali Therapeutics by 42.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company's stock valued at $59,373,000 after buying an additional 1,308,619 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Denali Therapeutics by 269.4% in the 1st quarter. Millennium Management LLC now owns 1,493,068 shares of the company's stock valued at $20,298,000 after buying an additional 1,088,844 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.

Insider Activity

In other news, insider Alexander O. Schuth sold 2,937 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider owned 242,346 shares of the company's stock, valued at approximately $3,291,058.68. This trade represents a 1.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ryan J. Watts sold 495,282 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the completion of the transaction, the chief executive officer directly owned 253,071 shares in the company, valued at approximately $3,796,065. This represents a 66.18% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 501,962 shares of company stock valued at $7,520,799. Company insiders own 12.50% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.